Clinical trialPhase 1 / Phase 2Completed
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- May 2008
- Ended
- 29 March 2019
- Enrollment
- 43 participants
- Sites
- 3
- Primary outcomes
- Response Rate
- Sponsor type
- Academic / other
- Results posted
- 9 July 2020
- Last update
- 9 July 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 9 July 2020
- Primary outcome
- Response RateTemozolomide and Everolimus: 16 of 40Values: ParticipantsTime frame: 2 yearsNo analysis posted for this outcome (outcome 1)
- Participants
- Temozolomide and Everolimus: 43 started, 43 completed
- Serious adverse events
- Temozolomide and Everolimus: 15 of 43Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
- PFS · Progression-free Survival
- Temozolomide and Everolimus 15.4 (9.4 to 20.4), n=43 [median months, 95% Confidence Interval]
- To Determine the Safety and Tolerability of This Drug Combination.
- Grade 3 or 4 Lymphopenia: Temozolomide and Everolimus 19/43 [Participants] (first of 6 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This research study will test the safety of RAD001 in combination with temozolomide.
Detailed description public domain (ClinicalTrials.gov)
* Participants will take RAD001 by mouth daily. They will also take temozolomide by mouth daily for one week, followed by a one-week break period. This one-week on/one week off schedule for temozolomide will continue for the duration of the treatment. * After the first month of treatment, there will be a 7-day observation period during which no study medication will be taken to observe for any side effects. * During all treatment cycles (1 cycle is 28 days in length) participants will have a physical exam and will be asked questions about their general health and specific questions about any problems they may be experiencing. Initially, participants will come in every other week. At each of these visits, blood work will be taken to monitor the participants health. * After every 2 months of treatment, participants will have a CT scan or MRI done to see how the medication is working.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Response Rate [2 years]. Count Of Participants, Participants. Temozolomide and Everolimus (n=40): 16.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival [2 years]. Median, months (95% Confidence Interval). Temozolomide and Everolimus (n=43): 15.4 (9.4 to 20.4).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
To Determine the Safety and Tolerability of This Drug Combination. [2 years]. Count Of Participants, Participants. Grade 3 or 4 Lymphopenia: Temozolomide and Everolimus (n=43): 19. Grade 3 or 4 thrombocytopenia: Temozolomide and Everolimus (n=43): 7. Grade 3 or 4 mucositis: Temozolomide and Everolimus (n=43): 1. Grade 3 or 4 hyperglycemia: Temozolomide and Everolimus (n=43): 8. Grade 3 or 4 AST Increase: Temozolomide and Everolimus (n=43): 4. Grade 3 or 4 Leukocyte decrease: Temozolomide and Everolimus (n=43): 7.